Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | ENDURANCE trial: KRd versus VRd for initial therapy of NDMM

Shaji Kumar • 1 Jun 2020
ASCO 2020
Multiple Myeloma Bortezomib Carfilzomib Dexamethasone Lenalidomide
ENDURANCE

Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses the results of the ENDURANCE trial (NCT01863550), a Phase III study of bortezomib, lenalidomide, and dexamethasone (VRd) compared to carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (NDMM). Dr Kumar reveals that VRd remains the standard triplet induction regimen in standard and intermediate-risk NDMM. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Shaji Kumar

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
Bruno Paiva et al. • 25 Mar 2024
1:17
Novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
Shaji Kumar • 11 May 2023
1:18
Overview of the updated NCCN Clinical Practice Guidelines for systemic AL amyloidosis
Shaji Kumar • 11 May 2023
1:26
Evaluating the efficacy of ixazomib, cyclophosphamide and dexamethasone in amyloidosis
Shaji Kumar • 11 May 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals